Today on the show, I’m joined by Michael Montalto, vice president of precision medicine at Amgen. Amgen is widely recognized as one of the most successful pharmaceutical companies in translating research and development into approved therapies. A key part of that success comes from their focus on precision medicine, and Mike brings a unique perspective from the forefront of that work. <a href="https://www.genialis.com/2025/07/24/how-to-have-the-biggest-impact-on-patients-a-career-of-invention-innovation-and-implementation-tpm-podcast-48/">⁠⁠TPM E48 highlights &gt;⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>Episode 48 links:<ul><li><a href="https://www.amgen.com">Amgen</a></li><li><a href="https://www.linkedin.com/in/mcmontalto/">Michael Montalto on LinkedIn</a></li><li><a href="https://www.genialis.com/2025/07/21/assessing-confidence-in-genetic-variants-identified-in-rna-seq-data/">Genialis presents a poster at ISMB/ECCB 2025⁠</a></li></ul>

Mida Pezeshkian, Stema_cg | Launching products in healthcare: The most important framework is flexibility | TPM podcast #49

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.